AC Immune SA reported that Janssen Pharmaceuticals has temporarily paused enrollment, for operational reasons, in the ongoing Phase 2b ReTain trial of anti-phospho-tau vaccine ACI-35.030/JNJ-2056 in preclinical Alzheimer’s disease, after a pre-specified interim immunogenicity threshold was met and without any new safety concerns. The company said the pause does not affect its liquidity and reaffirmed that existing capital should fund operations into the third quarter of 2027, while it prepares to deliver multiple 2026 clinical readouts across its Alzheimer’s, Parkinson’s and NLRP3 inflammasome programs and to report fourth-quarter 2025 earnings on March 12, 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.